Sugi Predict

Sugi Predict / Compounds / SCHEMBL710858

SCHEMBL710858

SCHEMBL710858

CC(C)Oc1cc(OCc2ccccc2)cc(-c2nc3cc(-c4ccccc4C(F)(F)F)cnc3[nH]2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCD O00767 1/20 0.43
▸ GCK P35557 1/20 0.39
▸ TRPA1 O75762 1/20 0.37
▸ FFAR1 O14842 1/20 0.35
▸ MCL1 Q07820 1/20 0.35
▸ PPARG P37231 2/20 0.34
▸ PPARA Q07869 2/20 0.34
▸ FFAR4 Q5NUL3 1/20 0.34
▸ NR1H2 P55055 3/20 0.34
▸ NR1H3 Q13133 2/20 0.34
▸ PPARD Q03181 1/20 0.34
▸ PTGES O14684 3/20 0.33
▸ CHEK2 O96017 1/20 0.33
▸ PSEN1 P49768 1/20 0.33
▸ PSEN2 P49810 1/20 0.33
▸ APH1B Q8WW43 1/20 0.33
▸ NCSTN Q92542 1/20 0.33
▸ APH1A Q96BI3 1/20 0.33
▸ PSENEN Q9NZ42 1/20 0.33
▸ USP1 O94782 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL710843 0.88 GCK (0.41) GCKFFAR1MCL1FFAR4CHEK2
SCHEMBL711183 0.87 GCK (0.42) SCDGCKMCL1CHEK2
SCHEMBL709868 0.87 GCK (0.41) SCDGCKFFAR1MCL1PTGES
SCHEMBL712420 0.86 SCD (0.42) SCDTRPA1FFAR1MCL1PPARG
SCHEMBL711145 0.86 SCD (0.42) SCDTRPA1FFAR1MCL1PPARG
SCHEMBL710173 0.86 GCK (0.44) GCKMCL1CHEK2
SCHEMBL712834 0.86 MAPT (0.40) GCKFFAR1MCL1
SCHEMBL711270 0.85 GRIN1 (0.44) GCK
SCHEMBL13608360 0.85 TRPA1 (0.41) TRPA1
SCHEMBL711343 0.83 GCK (0.41) GCKFFAR1MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 — — EP disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 — — US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 — — US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 — — US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 — — US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 — — US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 — — US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 — — EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK SCD 2937/4885GCK 1/4885TRPA1 3722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.